Close Menu

Rheonix

The endpoint RT-PCR test is processed on the company's Encompass CARD cartridge, which runs on Rheonix's Encompass MDx workstation.

Test makers are preparing to ramp up production of new SARS-CoV-2 assays and designated testing systems in anticipation of increased demand.

SARS-CoV-2 viral material is available for test validation, and the FDA is conducting a rolling review process with an abbreviated submission template.

The Ithaca, New York-based firm has submitted its molecular diagnostic instrument along with a test to detect chlamydia, gonorrhea, and trichomonas.

The CDC says that the number of people in the US who have been infected with diseases carried by mosquitoes, ticks, and flea bites have more than tripled in recent years.

The researchers built a combination nucleic acid-antibody test for the disease using an approach they said could be generally useful for rapid test development.

Rheonix has won an administrative supplement to an existing SBIR grant to develop the Zika test using its CARD cartridge and Encompass Optimum platform.

The firm's dual assay for host antigen to HIV as well as viral RNA was described in a proof-of-principle study earlier this year. 

Rheonix Raises $28.6M

The Ithaca, New York-based firm will use the financing to ramp up commercialization of its molecular diagnostic testing platforms.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.